If you have been reading about IGF-1 and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2025-10-30. Numbers and descriptions here follow the published literature rather than marketing material.
Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.
AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.
Quality varies among research-grade suppliers, so certificates of analysis and independent testing are important for verification. A typical certificate reports purity by HPLC, identity by mass spectrometry, appearance, and sometimes residual solvents or water content. AOD9604 is often sold as a research chemical not intended for human consumption, and labels can be inaccurate. Common misconceptions include treating the peptide as a form of growth hormone, assuming supplement status, or expecting approved-drug quality from unregulated products.
AOD9604 is commonly supplied as a white to off-white lyophilized powder. The powder is typically stored at -20 °C or below, protected from light and moisture, because peptides can degrade through oxidation, hydrolysis, or aggregation. If it is reconstituted for laboratory use, an appropriate aqueous buffer or solvent is chosen, and the solution is kept cold and handled to avoid repeated freeze-thaw cycles. These practices support stability but do not imply suitability for human use.
Identity and purity are usually assessed with reversed-phase high-performance liquid chromatography and mass spectrometry. Reversed-phase HPLC separates the peptide from related impurities and can estimate purity by ultraviolet absorbance, while mass spectrometry confirms the molecular mass and detects modifications. Peptide mapping, amino acid analysis, and disulfide mapping may be used when the sequence or disulfide arrangement must be verified. Because AOD9604 contains cysteine residues, oxidation and disulfide isomers are possible quality concerns in synthetic batches.
| Property | Value | Notes |
|---|---|---|
| Primary research area | Obesity and metabolic regulation | Studied in cell, animal, and human models |
| Highest reported trial phase | Phase II | Public summaries describe mixed results |
| Common route in trials | Subcutaneous injection | Typical for peptide therapeutics |
| Regulatory example | 2013 Australian anti-doping review | Classification was debated at the time |
| Approval status | Not approved as a human medicine | Status can change by jurisdiction |
The fragment includes residues that can form an internal disulfide bond between two cysteine positions. This structural feature can influence how the peptide folds and how stable it is in solution. AOD-9604 differs from full-length hGH in size and receptor interactions; it does not contain the entire growth hormone sequence. Published descriptions sometimes use slightly different residue numbering, so sequence information should be checked against primary sources. The molecule is small compared with intact hGH, which affects analytical detection and purification approaches.
Interest in AOD-9604 arose from attempts to separate metabolic effects from growth effects attributed to hGH. Early work explored whether the fragment could influence lipolysis or fat oxidation without promoting growth. Those questions remain partly unresolved because human data are limited and results have varied across studies. The peptide is not a hormone replacement for hGH and is not equivalent to hGH in clinical use. Its research history includes both laboratory studies and commercial marketing claims that are not the same as regulatory approval.
AOD-9604 is a synthetic peptide whose structure corresponds to a C-terminal segment of human growth hormone. It is often described as hGH fragment 176-191, a 16-amino-acid sequence. The peptide was designed to isolate a region of hGH associated with fat metabolism while avoiding the full hormone's growth-promoting actions. Laboratory and commercial materials typically present it as a lyophilized powder for research use. Its identity is defined by amino acid sequence, not by a single brand.
Regulatory treatment of AOD-9604 is shaped by its classification as a peptide hormone. The World Anti-Doping Agency lists it as a prohibited substance, and many national anti-doping organizations adopt that list. It does not hold approval as a prescription medicine in the United States, the European Union, or other major markets. Products sold online are frequently labeled for research use only and may not undergo independent quality testing. Import and possession rules differ by country, so legal status depends on local law.
Proposed mechanisms for AOD-9604 focus on fat cells. Laboratory studies suggest the peptide can increase lipolysis, the breakdown of stored fat, and reduce lipogenesis, the formation of new fat. Unlike full human growth hormone, it does not appear to stimulate substantial IGF-1 production in the studies reported so far. Some evidence points to beta-adrenergic signaling, but the precise receptor targets and downstream pathways remain unresolved. The fragment is not thought to act through the classical growth hormone receptor.
== Ethylene derivatives == These are generally mustard oils, which are characterized by a burning taste; their principal occurrence is in mustard and Tropaeolum seeds. Sinigrin, or the potassium salt of inyronic acid not only occurs in mustard seed, but also in black pepper and in horseradish root. Hydrolysis with barium hydroxide, or decomposition by the ferment myrosin, gives glucose, allyl mustard oil and potassium hydroxide. Sinalbin occurs in white pepper; it decomposes to the mustard oil, glucose and sinapin, a compound of choline and sinapic acid. Jalapin or Scammonin occurs in scammony; it hydrolyses to glucose and jalapinolic acid.
Narrated by Paul Brightwell, produced by David Sington, directed by David McNab, made by Dox Productions 4 March The Engines That Came in from the Cold, about the Russian N1 rocket with an unexpected and surprising outcome to the documentary, and a reference to the 1963 book The Spy Who Came in from the Cold; George Mueller, head of Apollo programme from 1963 to 1969; Charles Vick of the Federation of American Scientists; Sergei Korolev, chief designer at OKB-1; Vasily Mishin, deputy chief designer at OKB-1, had done calculations showing that to get a cosmonaut on the Moon, it required a 100 tonne vehicle in orbit, which would require a 2,000 tonne vehicle at lift-off; Valentin Anisimov, chief designer at Kuznetsov Design Bureau, and how Korolev approached the Kuznetsov company, to make the new rocket engines for the proposed N1 rocket launcher, but it was too new and large to develop from scratch, so thirty pre-existing engines would be deployed, and the pre-burner which powered the rocket pumps would become a closed cycle, to improve power by 25%, but this was vastly untested; the first twelve launches would be uncrewed, followed by two test crewed launches, and the Soviet limited budget meant that development was not at a sufficient stage (that NASA would have arrived at) before the launches were carried out; this first uncrewed launch took place on 21 February 1969, and one minute into the flight, the rocket exploded; the N1 had a thrust of 4,500 tonnes at launch; the N1 second launch took place on 3 July 1969, after the engine control system was modified, and a few seconds after launch the engine cut out, and the whole N1 launcher fell onto the launch pad, causing total catastrophic results - this explosion stopped any further Soviet Union attempt to reach the Moon with a crewed rocket, the launch pad damage was unrecoverable; two weeks later Apollo 11 landed on the Moon; the N1 next launch was on 26 June 1971, with a rebuilt launch pad, and this launch exploded one minute into the flight; the fourth launch of the N1 on 23 November 1972 exploded two minutes into the flight; by the mid-1970s the Kuznetsov NK-33 closed-cycle engine, for the N1, had been sufficiently tested in its development lifetime; the Soviet Moon mission was around four years behind NASA, and when the engines were finally sufficiently tested, the whole Soviet Moon programme was stopped in 1974; any N1 engines and systems were instructed to be removed, to eliminate its knowledge; only in the early 1990s did knowledge of the N1 first appear; Bob Ford of Lockheed Martin and Bill Hoffman of Aerojet; Kuznetsov had nonetheless kept around sixty NK-33 engines in Samara - the home of Soviet rocketry, and wanted to show these engines to visitors from Aerojet; after a successful test of an NK-33 at Sacramento in October 1995, the NK-33 was developed into the RD-180, which powered the American Lockheed Martin Atlas III rocket; John Karas, of Lockheed Martin, at the first launch of an American rocket, on 24 May 2000 of the Eutelsat 36A satellite, that was powered by a Russian engine - the RD-180, which was twice as powerful as the NK-33, and one engine could replace five engines of the previous Atlas II; Vladimir Chvanov and Boris Katorgin, designers at NPO Energomash; the American rocket engineers had viewed the closed-cycle method as far too dangerous, and it was dangerous, but Russian engineers had developed new stainless steel alloys to largely overcome this danger. Narrated by Jaye Griffiths, produced by Hamish Barbour, directed by, made by Ideal World Productions 17 June The Day the Oceans Boiled, about the Earth's environment; 55 million years ago, the Earth was 6C hotter than it is now, with no ice caps, and trees grew at Antarctica, the temperature became 8C hotter, known as the Paleocene-Eocene Thermal Maximum; mammals shrunk in how large; since 55m years ago, carbon dioxide has been absorbed by plants, cooling the Earth; climate models were derived from weather forecast models; Peter Cox (climatologist) of the Met Office, and carbon sinks, and how each year 6 billion tonnes of carbon dioxide enters the atmosphere, but the effect appears to be only from around 3 billion tonnes; Antonio Nobre of the National Institute of Amazonian Research - he found that the Amazon forest, and its 500 million hectares of trees, was a much bigger carbon sink than presumed - it could be absorbing three-quarters of the carbon dioxide of all the world's vehicles; the Greenland Ice Sheet Project, and Geoffrey Hargreaves at the National Science Foundation Ice Core Facility (NICL) in Colorado, and ice cores from the Vostok Station; the Earth has warmed and cooled in a 100,000 years cycle; the Met Office model predicted that after 2050, due to shortage of rainfall seasons, the Amazon forest would not act as a carbon sink; Carlos Nobre (scientist) and dry seasons, and the possible danger of fire, caused by changes in the tropical climate; Richard Corfield (scientist); Philip D. Gingerich of the University of Michigan; Santo Bains was researching the Paleocene-Eocene boundary, so went to the Gulf Coast Repository, and looked at Core 690 drilled by JOIDES Resolution of the Ocean Drilling Program from the Weddell Sea, and concluded that rapid changes in Earth temperature came from methane clathrates (methane hydrates); geologist Euan Nisbet; the Earth returned to lower temperatures after 60,000 years. Narrated by Matthew Zajac, directed by David Sington, made by Dox Productions 24 June The Fish That Time Forgot, about the coelacanth; Margery Courtney Latimer in 1938 of the Natural History Museum, London, and a fish caught at East London; J. L. B. Smith, from Grahamstown, of Rhodes University; the American Museum of Natural History; evolutionary biologist John McCusker; the Comoro Islands, run by the French, near Madagascar, where another fish was found in 1952; Mike Ruton; Robin Stobbs; the JAGO (German research submersible) and Hans Fricke of the Max Planck Institute for Behavioral Physiology, who found a live fish on 17 January 1987; Susan Jewett of the National Museum of Natural History in Washington; on 30 July 1998, a live female fish is found on a beach in Indonesia by Mark Erdmann. Narrated by Robert Lindsay, produced by Ron Ackerman, directed by Celia Lowenstein, made by Diverse Productions with Nova 8 July The Secret Life of the Mouse, about the laboratory mouse; zoologist Sam Berry of UCL; mouse geneticist Jo Peters of MRC Harwell; Irving Weissman; most genetic research is done with mice, with 25 million a year; Steve Brown, Director of MRC Harwell; the mouse has 99.9% of the genes of humans; the Jackson Laboratory has 1m mice and around 1,000 human staff, with 2,500 strains of mice, who have mouse models of human diseases, and mice breed much quicker than humans do; Beverly Paigen; in one year, there are three generations of mice; twenty Nobel prizes have depended on mouse research; Cliffe Rosen of the Maine Center of Osteoporosis Research; scientists want mutant mice for each gene; Charles Vacanti of the University of Massachusetts Medical School, whose cartilage research led to a mouse having an artificial cartilage human ear grown on its back; Philip Leder of Harvard Medical School, who placed a patent on a mouse; a fluorescent mouse; Hank Greely of Stanford University; it ends with the opening lines from A Tale of Two Cities. Narrated by Stephen Fry, produced by David Paterson, directed by Kevin Hull, made by BOA 2001. The documentary has overtones of the music video of the 2001 Where's Your Head At, made in the same year as the documentary 15 July Saving the Leaning Tower, a documentary chronicling the dramatic rescue of one of the world’s most iconic landmarks. By the late 1980s, the Leaning Tower of Pisa was on the brink of collapse, its southward tilt increasing steadily and threatening catastrophic failure. Alarm spread after the sudden fall of a medieval bell tower in Pavia in 1989, which convinced authorities to close Pisa’s monument to the public. An international committee of engineers, geologists, and historians was formed to save the tower, among them British civil engineer John Burland. Through detailed investigation, the team uncovered the structural weaknesses behind the marble façade and the unstable soils beneath Pisa. Computer models showed the tower should already have collapsed. Temporary steel tendons and 600 tonnes of lead counterweights prevented immediate disaster, but the tower’s fate remained uncertain. Burland proposed a novel, delicate solution: controlled “soil extraction” below the northern side to allow the tower to gently tilt back to stability. The project was plagued by risks, political disputes, and near-disasters, including the “Black September” of 1995, when freezing the foundations caused the tower to lurch alarmingly. Despite opposition, the soil extraction method was eventually approved in 1998. Over two years, engineers removed around 70 tonnes of soil, gradually reducing the lean by half a meter without visible alteration to the monument. By June 2001, the tower had been successfully stabilized, restored to the inclination it had in the 18th century, and reopened to the public. The operation was hailed as one of the greatest feats of modern civil engineering, ensuring the survival of Pisa’s unique heritage for centuries to come. The documentary presents not only the technical challenges but also the cultural, historical, and emotional significance of preserving this medieval masterpiece. 13 October Battle of the Robots: The Hunt for AI, about the work of Hugo de Garis, Rodney Brooks, and Steve Grand (roboticist); the documentary opens with the archetypal and iconic robot HAL 9000 from the 1968 2001: A Space Odyssey (film) and The Blue Danube; Igor Aleksander, who worked in neural systems at Imperial College London, and his views on the likelihood of computational intelligence; Dan Dennett; British roboticist Steve Grand, of North Somerset made the world's first AI computer game Creatures in 1996, and was designing a glider that could teach itself; Blay Whitby of the University of Sussex; the MIT Computer Science and Artificial Intelligence Laboratory and Brian Scassellati, who was designing a social robot called Cog (project); Belgian Walter De Brouwer of Starlab in Belgium; engineer Kevin Warwick of the University of Reading at the 2001 Royal Society Prizes for Science Books (Aventis Prize for Science Books), won by Robert Kunzig. Narrated by Patrick Forbes, produced by Nicolas Kent 28 October Bioterror, an Equinox Special, about biological weapons, with Judith Miller and her 2001 book Germs: Biological Weapons and America's Secret War; Robert Kadlec of the National War College; science writer William Broad; the ATCC in Manassas, Virginia; microbiologist William C. Patrick III; the 2001 anthrax attacks; microbiologist Richard O. Spertzel; geneticist Matthew Meselson; Gennady Lepyoshkin, Director from 1987 to 2001 of a Russian secret biological research site; Jonathan B. Tucker; Chris Shays; Andrew C. Weber; Sergei Popov (bioweaponeer) had worked at the State Research Center for Applied Microbiology in Obolensk, Moscow Oblast. Produced by Matthew Collins, directed by Kirk Wolfinger, made by WGBH. Shown on Tuesday 20 November 2001 on The Nature of Things in Canada, and on Nova, and on Nova on Tuesday 13 November 2001
2 CH4 + 3 O2 → 4 H2O + 2 CO CH4 + O2 → 2 H2O + C See the alkane heat of formation table for detailed data. The standard enthalpy change of combustion, ΔcH⊖, for alkanes increases by about 650 kJ/mol per CH2 group. Branched-chain alkanes have lower values of ΔcH⊖ than straight-chain alkanes of the same number of carbon atoms, and so can be seen to be somewhat more stable.
Roller chains are used in low- to mid-speed drives at around 600 to 800 feet per minute; however, at higher speeds, around 2,000 to 3,000 feet per minute, V-belts are normally used due to wear and noise issues. A bicycle chain is a roller chain. Bicycle chains may have a master link, or may require a chain tool for removal and installation. A similar but larger and thus stronger chain is used on most motorcycles although it is sometimes replaced by either a toothed belt or a shaft drive, which offer lower noise level and fewer maintenance requirements. A timing chain is a roller chain used in some internal combustion automobile engines to drive a camshaft. Very high performance engines often use gear drive, and starting in the early 1960s toothed belts were used by some manufacturers.
The production of Champagne and many sparkling wines requires a second fermentation to occur in the bottle in order to produce the carbonation necessary for the style. A small amount of sugared liquid is added to individual bottles, and the yeast is allowed to convert this to more alcohol and carbon dioxide. The lees are then ricked into the neck of the bottle, frozen, and expelled via pressure of the carbonated wine.
Sources: en.wikipedia.org
=== Citizens' band and personal radio services === Citizens' band radio is allocated in many countries, using channelized radios in the upper HF part of the spectrum (around 27 MHz). It is used for personal, small business and hobby purposes. Other frequency allocations are used for similar services in different jurisdictions, for example UHF CB is allocated in Australia. A wide range of personal radio services exist around the world, usually emphasizing short-range communication between individuals or for small businesses, simplified license requirements or in some countries covered by a class license, and usually FM transceivers using around 1 watt or less.
== Similar approaches == The idea of using protein design to accomplish the same goals as DNA origami has surfaced as well. Researchers at the National Institute of Chemistry in Slovenia are working on using rational design of protein folding to create structures much like those seen with DNA origami. The main focus of current research in protein folding design is in the drug delivery field, using antibodies attached to proteins as a way to create a targeted vehicle.
=== PRC government === The Chinese government said that producers violating the law "could have their licenses revoked and be handed over to law enforcement organs". A senior Agriculture Ministry official said that of a quarter of a million feed-makers and animal farms inspected for melamine contamination, inspectors found more than 500 engaged in "illegal or questionable practices". Some 3,700 tonnes of feed with excessive melamine were seized. Hong Kong regulators have requested certification of exported eggs, but the central government has not yet mounted a centralised response; although mainland authorities already require eggs to be certified as free of avian influenza and Sudan red dye prior to export following previous food-safety scares, the AQSIQ has declined nationwide testing. Local government, for example Guangdong authorities, have increased random inspections at poultry farms. They declared to "harshly crack down on the unlawful behaviour of illegally manufacturing, selling and using melamine".
==== Anticoagulants ==== Anticoagulants are considered more aggressive than antiplatelet drugs. Anticoagulants work by interfering with various clotting factors to lengthen the time for coagulation. This can be achieved by either reducing the formation of bioactive clotting factors or accelerating the inactivation of clotting factors.
Sources: en.wikipedia.org
No major medicines regulator appears to have approved AOD-9604 for human therapeutic use. It has been studied in clinical trials, but those programs did not result in a marketed drug.
It became prominent during a 2013 Australian sports investigation that examined whether it was a prohibited growth-hormone-related substance. Subsequent interpretations and list updates have varied, so current rules should be checked directly.
Published summaries generally report limited or inconsistent weight-loss effects, and complete trial data are not widely available. The studies were not sufficient to establish it as an effective obesity treatment.
Lyophilized AOD9604 is generally kept at -20 °C or colder, desiccated, and protected from light. Reconstituted solutions are usually refrigerated and handled to minimize repeated freeze-thaw cycles. These are general laboratory handling practices, not instructions for human use.